Muscle Insider
New member
Myths Regarding TRT
By George Touliatos, MD
The most common fears regarding TRT are:
1) Prostate cancer
2) Cardiovascular disease
First of all, we have to know that prostate cancer occurs in men with low testosterone. The type of cancer is not androgen based. On the contrary, uncontrolled estrogens are responsible for the proliferation of cancerous cells in prostatic parenchyma. Testosterone deficiency is accompanied by low muscle mass, that in turn leads to visceral fat accumulation. This is a bad type of adipose tissue, linked to release of inflammation and cytokine release (interleukin-6 and tumor necrosis factor). Visceral fat is plentiful in the aromatase enzyme, responsible for convertibility to estrogen. Moreover, men with hypogonadism are more likely to develop breast tissue enlargement, known as gynecomastia.
The direct correlation between testosterone administration and prostatic malignancy has been debunked. Professor Abraham Morgentaler, a top urologist from Harvard University, has explained this thoroughly. Furthermore, his pioneering research explained that even the use of testosterone while prostatic cancer occurs can be managed. Based on the androgen receptors (AR) theory, saturation of AR after a dose of testosterone will avoid extra assimilation of the main androgen. As long estrogens are optimized and controlled, this is achieved by measuring the estrone (E1), one of the three types of estrogens that has a high affinity for cellular proliferation. E1 can be blocked by using a sulfated compound, DIM, plentifully found in broccoli. Also, a mild use of an aromatase inhibitor (AI) such as anastrozole can prevent E2 from spiking. And the blockage of reducing T= > DHT by 5-alpha reductase inhibitors (dutasteride, finasteride) will ensure there is no DHT to feed up the prostate.
WATCH EPISODE 205 OF ASK DR TESTOSTERONE: "WHAT CYCLE IS GOOD FOR A 21 YEAR OLD?"
[embedded content]
The point with these medications is that blocking one metabolite of T (DHT) will increase the other one (E2). This is why we need to use an anti-estrogen while on anti-androgens. Plus, while on finasteride/dutasteride we must not use any other compound besides testosterone. No other AAS can be blocked (DHEA, DHT, mesterolone) by 5-alpha reductase inhibitors. The fact about testosterone and the prostate is that testosterone will be reduced to a potent androgen, dihydrotestosterone (DHT), that is able to enlarge the gland (benign prostatic hyperplasia or BPH). However, not all men can develop this under TRT, based on their PSA and genetic predisposition, family history. Certainly, BPH is not a malignant condition. Besides, elevated PSA can be the result of:
- Prostatitis
- Ejaculation
- Riding a motorcycle
This is usually why after taking antibiotics, PSA might lower and when there is absence of sexual intercourse for 72 hours.
As far as cardiovascular disease, it’s known that low testosterone is associated with CVD. First, because testosterone deficiency is linked to visceral fat accumulation. That, in turn, is linked to insulin resistance (A1C >5.5%) and dyslipidemia (LDL >100) – but also with enlarged midsection circumference ( >100cm). These are 3 of 4 factors consisting of the metabolic syndrome (MS), leading to CVD. Moreover, testosterone is able to synthesize NO (nitric oxide), the molecule that is able to be a vasodilator to coronary arteries and provide an O2 supply to the myocardium. Furthermore, the fingertips of T= > E2 will play a protective role to the arterial endothelium, raising HDL, the good cholesterol that cleans up the arterial lumen from cholesterol deposits. For these reasons, the main androgen and TRT is the Foundation of Youth in men’s health.
Men are aging physically and mentally because of hypogonadism in middle-age crisis. Fortunately, these myths have been dispelled. The problem arises when patients either abuse testosterone or have uncontrolled metabolites and aren’t optimized. They definitely need to monitor their blood work by annual follow-ups that include: TT, FT, E2, PRL, SHBG, DHEAS, PSA, CBC, A1C.
Realize that abuse of TRT can lower HDL, leading to erythrocytosis (the most common side effect), OSA (snoring), kick systemic blood pressure, nipple tenderness (aromatization by excessive estrogen), and potentially lead to BPH/ PSA elevation.
TRT is not about getting jacked and having five erections a day. It’s more than body composition and libido. Testosterone is vital for metabolic reasons (obesity, DM2, MS) depression, anemia, and osteoporosis. It depends on the use whether this wonder medication becomes a poison and spreads the bad reputation amongst medical community.
George Touliatos, MD is an author, lecturer, champion competitive bodybuilder and expert in medical prevention regarding PED use in sports. Dr. Touliatos specializes in medical biopathology and is the medical associate of Orthobiotiki.gr and Medihall.gr, Age Management and Preventive Clinics in Athens, Greece. Heis the author of four Greek books on bodybuilding, has extensively developed articles for www.anabolic.org and is the medical associate for the book “Anabolics, 11th Edition” (2017). Dr. Touliatos has been a columnist for the Greek editions of MuscleMag and Muscular Development magazines and has participated in several seminars across Greece and Cyprus, making numerous TV and radio appearances, doing interviews in print and online. His personal website is https://gtoul.com/
DISCUSS ON OUR FORUMSSUBSCRIBE TO MD TODAY
GET OFFICIAL MD STUFFVISIT OUR STORE
SUBSCRIBE TO OUR NEWSLETTER
ALSO, MAKE SURE TO FOLLOW US ON:
FACEBOOKTWITTERINSTAGRAM YOUTUBE
Myths Regarding TRT
By George Touliatos, MD
The most common fears regarding TRT are:
1) Prostate cancer
2) Cardiovascular disease
First of all, we have to know that prostate cancer occurs in men with low testosterone. The type of cancer is not androgen based. On the contrary, uncontrolled estrogens are responsible for the proliferation of cancerous cells in prostatic parenchyma. Testosterone deficiency is accompanied by low muscle mass, that in turn leads to visceral fat accumulation. This is a bad type of adipose tissue, linked to release of inflammation and cytokine release (interleukin-6 and tumor necrosis factor). Visceral fat is plentiful in the aromatase enzyme, responsible for convertibility to estrogen. Moreover, men with hypogonadism are more likely to develop breast tissue enlargement, known as gynecomastia.
The direct correlation between testosterone administration and prostatic malignancy has been debunked. Professor Abraham Morgentaler, a top urologist from Harvard University, has explained this thoroughly. Furthermore, his pioneering research explained that even the use of testosterone while prostatic cancer occurs can be managed. Based on the androgen receptors (AR) theory, saturation of AR after a dose of testosterone will avoid extra assimilation of the main androgen. As long estrogens are optimized and controlled, this is achieved by measuring the estrone (E1), one of the three types of estrogens that has a high affinity for cellular proliferation. E1 can be blocked by using a sulfated compound, DIM, plentifully found in broccoli. Also, a mild use of an aromatase inhibitor (AI) such as anastrozole can prevent E2 from spiking. And the blockage of reducing T=> DHT by 5-alpha reductase inhibitors (dutasteride, finasteride) will ensure there is no DHT to feed up the prostate.
WATCH EPISODE 205 OF ASK DR TESTOSTERONE: "WHAT CYCLE IS GOOD FOR A 21 YEAR OLD?"
The point with these medications is that blocking one metabolite of T (DHT) will increase the other one (E2). This is why we need to use an anti-estrogen while on anti-androgens. Plus, while on finasteride/dutasteride we must not use any other compound besides testosterone. No other AAS can be blocked (DHEA, DHT, mesterolone) by 5-alpha reductase inhibitors. The fact about testosterone and the prostate is that testosterone will be reduced to a potent androgen, dihydrotestosterone (DHT), that is able to enlarge the gland (benign prostatic hyperplasia or BPH). However, not all men can develop this under TRT, based on their PSA and genetic predisposition, family history. Certainly, BPH is not a malignant condition. Besides, elevated PSA can be the result of:
- Prostatitis
- Ejaculation
- Riding a motorcycle
This is usually why after taking antibiotics, PSA might lower and when there is absence of sexual intercourse for 72 hours.
As far as cardiovascular disease, it’s known that low testosterone is associated with CVD. First, because testosterone deficiency is linked to visceral fat accumulation. That, in turn, is linked to insulin resistance (A1C>5.5%) and dyslipidemia (LDL>100) – but also with enlarged midsection circumference (>100cm). These are 3 of 4 factors consisting of the metabolic syndrome (MS), leading to CVD. Moreover, testosterone is able to synthesize NO (nitric oxide), the molecule that is able to be a vasodilator to coronary arteries and provide an O2 supply to the myocardium. Furthermore, the fingertips of T=> E2 will play a protective role to the arterial endothelium, raising HDL, the good cholesterol that cleans up the arterial lumen from cholesterol deposits. For these reasons, the main androgen and TRT is the Foundation of Youth in men’s health.
Men are aging physically and mentally because of hypogonadism in middle-age crisis. Fortunately, these myths have been dispelled. The problem arises when patients either abuse testosterone or have uncontrolled metabolites and aren’t optimized. They definitely need to monitor their blood work by annual follow-ups that include: TT, FT, E2, PRL, SHBG, DHEAS, PSA, CBC, A1C.
Realize that abuse of TRT can lower HDL, leading to erythrocytosis (the most common side effect), OSA (snoring), kick systemic blood pressure, nipple tenderness (aromatization by excessive estrogen), and potentially lead to BPH/ PSA elevation.
TRT is not about getting jacked and having five erections a day. It’s more than body composition and libido. Testosterone is vital for metabolic reasons (obesity, DM2, MS) depression, anemia, and osteoporosis. It depends on the use whether this wonder medication becomes a poison and spreads the bad reputation amongst medical community.
George Touliatos, MD is an author, lecturer, champion competitive bodybuilder and expert in medical prevention regarding PED use in sports. Dr. Touliatos specializes in medical biopathology and is the medical associate of Orthobiotiki.gr and Medihall.gr, Age Management and Preventive Clinics in Athens, Greece. Heis the author of four Greek books on bodybuilding, has extensively developed articles for www.anabolic.org and is the medical associate for the book “Anabolics, 11th Edition” (2017). Dr. Touliatos has been a columnist for the Greek editions of MuscleMag and Muscular Development magazines and has participated in several seminars across Greece and Cyprus, making numerous TV and radio appearances, doing interviews in print and online. His personal website is https://gtoul.com/
DISCUSS ON OUR FORUMS
SUBSCRIBE TO MD TODAY
GET OFFICIAL MD STUFF
VISIT OUR STORE
SUBSCRIBE TO OUR NEWSLETTER
ALSO, MAKE SURE TO FOLLOW US ON:
FACEBOOK
TWITTER
INSTAGRAM
YOUTUBE
Click here to view the article.
By George Touliatos, MD
The most common fears regarding TRT are:
1) Prostate cancer
2) Cardiovascular disease
First of all, we have to know that prostate cancer occurs in men with low testosterone. The type of cancer is not androgen based. On the contrary, uncontrolled estrogens are responsible for the proliferation of cancerous cells in prostatic parenchyma. Testosterone deficiency is accompanied by low muscle mass, that in turn leads to visceral fat accumulation. This is a bad type of adipose tissue, linked to release of inflammation and cytokine release (interleukin-6 and tumor necrosis factor). Visceral fat is plentiful in the aromatase enzyme, responsible for convertibility to estrogen. Moreover, men with hypogonadism are more likely to develop breast tissue enlargement, known as gynecomastia.
The direct correlation between testosterone administration and prostatic malignancy has been debunked. Professor Abraham Morgentaler, a top urologist from Harvard University, has explained this thoroughly. Furthermore, his pioneering research explained that even the use of testosterone while prostatic cancer occurs can be managed. Based on the androgen receptors (AR) theory, saturation of AR after a dose of testosterone will avoid extra assimilation of the main androgen. As long estrogens are optimized and controlled, this is achieved by measuring the estrone (E1), one of the three types of estrogens that has a high affinity for cellular proliferation. E1 can be blocked by using a sulfated compound, DIM, plentifully found in broccoli. Also, a mild use of an aromatase inhibitor (AI) such as anastrozole can prevent E2 from spiking. And the blockage of reducing T= > DHT by 5-alpha reductase inhibitors (dutasteride, finasteride) will ensure there is no DHT to feed up the prostate.
WATCH EPISODE 205 OF ASK DR TESTOSTERONE: "WHAT CYCLE IS GOOD FOR A 21 YEAR OLD?"
[embedded content]
The point with these medications is that blocking one metabolite of T (DHT) will increase the other one (E2). This is why we need to use an anti-estrogen while on anti-androgens. Plus, while on finasteride/dutasteride we must not use any other compound besides testosterone. No other AAS can be blocked (DHEA, DHT, mesterolone) by 5-alpha reductase inhibitors. The fact about testosterone and the prostate is that testosterone will be reduced to a potent androgen, dihydrotestosterone (DHT), that is able to enlarge the gland (benign prostatic hyperplasia or BPH). However, not all men can develop this under TRT, based on their PSA and genetic predisposition, family history. Certainly, BPH is not a malignant condition. Besides, elevated PSA can be the result of:
- Prostatitis
- Ejaculation
- Riding a motorcycle
This is usually why after taking antibiotics, PSA might lower and when there is absence of sexual intercourse for 72 hours.
As far as cardiovascular disease, it’s known that low testosterone is associated with CVD. First, because testosterone deficiency is linked to visceral fat accumulation. That, in turn, is linked to insulin resistance (A1C >5.5%) and dyslipidemia (LDL >100) – but also with enlarged midsection circumference ( >100cm). These are 3 of 4 factors consisting of the metabolic syndrome (MS), leading to CVD. Moreover, testosterone is able to synthesize NO (nitric oxide), the molecule that is able to be a vasodilator to coronary arteries and provide an O2 supply to the myocardium. Furthermore, the fingertips of T= > E2 will play a protective role to the arterial endothelium, raising HDL, the good cholesterol that cleans up the arterial lumen from cholesterol deposits. For these reasons, the main androgen and TRT is the Foundation of Youth in men’s health.
Men are aging physically and mentally because of hypogonadism in middle-age crisis. Fortunately, these myths have been dispelled. The problem arises when patients either abuse testosterone or have uncontrolled metabolites and aren’t optimized. They definitely need to monitor their blood work by annual follow-ups that include: TT, FT, E2, PRL, SHBG, DHEAS, PSA, CBC, A1C.
Realize that abuse of TRT can lower HDL, leading to erythrocytosis (the most common side effect), OSA (snoring), kick systemic blood pressure, nipple tenderness (aromatization by excessive estrogen), and potentially lead to BPH/ PSA elevation.
TRT is not about getting jacked and having five erections a day. It’s more than body composition and libido. Testosterone is vital for metabolic reasons (obesity, DM2, MS) depression, anemia, and osteoporosis. It depends on the use whether this wonder medication becomes a poison and spreads the bad reputation amongst medical community.
George Touliatos, MD is an author, lecturer, champion competitive bodybuilder and expert in medical prevention regarding PED use in sports. Dr. Touliatos specializes in medical biopathology and is the medical associate of Orthobiotiki.gr and Medihall.gr, Age Management and Preventive Clinics in Athens, Greece. Heis the author of four Greek books on bodybuilding, has extensively developed articles for www.anabolic.org and is the medical associate for the book “Anabolics, 11th Edition” (2017). Dr. Touliatos has been a columnist for the Greek editions of MuscleMag and Muscular Development magazines and has participated in several seminars across Greece and Cyprus, making numerous TV and radio appearances, doing interviews in print and online. His personal website is https://gtoul.com/
DISCUSS ON OUR FORUMSSUBSCRIBE TO MD TODAY
GET OFFICIAL MD STUFFVISIT OUR STORE
SUBSCRIBE TO OUR NEWSLETTER
ALSO, MAKE SURE TO FOLLOW US ON:
FACEBOOKTWITTERINSTAGRAM YOUTUBE
Myths Regarding TRT
By George Touliatos, MD
The most common fears regarding TRT are:
1) Prostate cancer
2) Cardiovascular disease
First of all, we have to know that prostate cancer occurs in men with low testosterone. The type of cancer is not androgen based. On the contrary, uncontrolled estrogens are responsible for the proliferation of cancerous cells in prostatic parenchyma. Testosterone deficiency is accompanied by low muscle mass, that in turn leads to visceral fat accumulation. This is a bad type of adipose tissue, linked to release of inflammation and cytokine release (interleukin-6 and tumor necrosis factor). Visceral fat is plentiful in the aromatase enzyme, responsible for convertibility to estrogen. Moreover, men with hypogonadism are more likely to develop breast tissue enlargement, known as gynecomastia.
The direct correlation between testosterone administration and prostatic malignancy has been debunked. Professor Abraham Morgentaler, a top urologist from Harvard University, has explained this thoroughly. Furthermore, his pioneering research explained that even the use of testosterone while prostatic cancer occurs can be managed. Based on the androgen receptors (AR) theory, saturation of AR after a dose of testosterone will avoid extra assimilation of the main androgen. As long estrogens are optimized and controlled, this is achieved by measuring the estrone (E1), one of the three types of estrogens that has a high affinity for cellular proliferation. E1 can be blocked by using a sulfated compound, DIM, plentifully found in broccoli. Also, a mild use of an aromatase inhibitor (AI) such as anastrozole can prevent E2 from spiking. And the blockage of reducing T=> DHT by 5-alpha reductase inhibitors (dutasteride, finasteride) will ensure there is no DHT to feed up the prostate.
WATCH EPISODE 205 OF ASK DR TESTOSTERONE: "WHAT CYCLE IS GOOD FOR A 21 YEAR OLD?"
The point with these medications is that blocking one metabolite of T (DHT) will increase the other one (E2). This is why we need to use an anti-estrogen while on anti-androgens. Plus, while on finasteride/dutasteride we must not use any other compound besides testosterone. No other AAS can be blocked (DHEA, DHT, mesterolone) by 5-alpha reductase inhibitors. The fact about testosterone and the prostate is that testosterone will be reduced to a potent androgen, dihydrotestosterone (DHT), that is able to enlarge the gland (benign prostatic hyperplasia or BPH). However, not all men can develop this under TRT, based on their PSA and genetic predisposition, family history. Certainly, BPH is not a malignant condition. Besides, elevated PSA can be the result of:
- Prostatitis
- Ejaculation
- Riding a motorcycle
This is usually why after taking antibiotics, PSA might lower and when there is absence of sexual intercourse for 72 hours.
As far as cardiovascular disease, it’s known that low testosterone is associated with CVD. First, because testosterone deficiency is linked to visceral fat accumulation. That, in turn, is linked to insulin resistance (A1C>5.5%) and dyslipidemia (LDL>100) – but also with enlarged midsection circumference (>100cm). These are 3 of 4 factors consisting of the metabolic syndrome (MS), leading to CVD. Moreover, testosterone is able to synthesize NO (nitric oxide), the molecule that is able to be a vasodilator to coronary arteries and provide an O2 supply to the myocardium. Furthermore, the fingertips of T=> E2 will play a protective role to the arterial endothelium, raising HDL, the good cholesterol that cleans up the arterial lumen from cholesterol deposits. For these reasons, the main androgen and TRT is the Foundation of Youth in men’s health.
Men are aging physically and mentally because of hypogonadism in middle-age crisis. Fortunately, these myths have been dispelled. The problem arises when patients either abuse testosterone or have uncontrolled metabolites and aren’t optimized. They definitely need to monitor their blood work by annual follow-ups that include: TT, FT, E2, PRL, SHBG, DHEAS, PSA, CBC, A1C.
Realize that abuse of TRT can lower HDL, leading to erythrocytosis (the most common side effect), OSA (snoring), kick systemic blood pressure, nipple tenderness (aromatization by excessive estrogen), and potentially lead to BPH/ PSA elevation.
TRT is not about getting jacked and having five erections a day. It’s more than body composition and libido. Testosterone is vital for metabolic reasons (obesity, DM2, MS) depression, anemia, and osteoporosis. It depends on the use whether this wonder medication becomes a poison and spreads the bad reputation amongst medical community.
George Touliatos, MD is an author, lecturer, champion competitive bodybuilder and expert in medical prevention regarding PED use in sports. Dr. Touliatos specializes in medical biopathology and is the medical associate of Orthobiotiki.gr and Medihall.gr, Age Management and Preventive Clinics in Athens, Greece. Heis the author of four Greek books on bodybuilding, has extensively developed articles for www.anabolic.org and is the medical associate for the book “Anabolics, 11th Edition” (2017). Dr. Touliatos has been a columnist for the Greek editions of MuscleMag and Muscular Development magazines and has participated in several seminars across Greece and Cyprus, making numerous TV and radio appearances, doing interviews in print and online. His personal website is https://gtoul.com/
DISCUSS ON OUR FORUMS
SUBSCRIBE TO MD TODAY
GET OFFICIAL MD STUFF
VISIT OUR STORE
SUBSCRIBE TO OUR NEWSLETTER
ALSO, MAKE SURE TO FOLLOW US ON:
YOUTUBE
Click here to view the article.
